HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Bernard Escudier Selected Research

temsirolimus

10/2015A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
3/2014Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
3/2014Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
12/2011Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
7/2011Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
12/2010Targeting mTOR in cancer: renal cell is just a beginning.
5/2009Sequential therapy in renal cell carcinoma.
9/2008Signaling inhibitors in metastatic renal cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Bernard Escudier Research Topics

Disease

101Renal Cell Carcinoma (Grawitz Tumor)
12/2015 - 07/2003
55Neoplasms (Cancer)
12/2015 - 03/2002
20Kidney Neoplasms (Kidney Cancer)
09/2015 - 04/2002
11Fatigue
11/2015 - 01/2007
10Neoplasm Metastasis (Metastasis)
11/2015 - 01/2006
8Carcinoma (Carcinomatosis)
11/2015 - 07/2005
8Disease Progression
03/2014 - 01/2007
8Melanoma (Melanoma, Malignant)
12/2011 - 03/2002
7Hypertension (High Blood Pressure)
08/2015 - 01/2007
5Anoxia (Hypoxia)
08/2015 - 01/2007
5Exanthema (Rash)
04/2012 - 01/2007
4Prostatic Neoplasms (Prostate Cancer)
11/2015 - 05/2009
4Diarrhea
05/2014 - 01/2007
3Proteinuria
12/2015 - 09/2013
3Pneumonia (Pneumonitis)
03/2014 - 08/2008
2Edema
12/2015 - 04/2012
2Kidney Diseases (Kidney Disease)
11/2014 - 02/2014
2Stomatitis
03/2014 - 08/2008
2Renal Insufficiency (Renal Failure)
09/2013 - 05/2007
2Cough
04/2012 - 06/2007
2Alopecia (Baldness)
12/2011 - 02/2009
2Dyspnea (Shortness of Breath)
09/2010 - 06/2007
2Asthenia
02/2010 - 12/2007
1Myocardial Infarction
12/2015
1Anemia
11/2015
1Body Weight (Weight, Body)
11/2015
1Urologic Neoplasms (Urological Cancer)
03/2015
1Cystinuria
01/2015
1Kidney Calculi (Kidney Stone)
01/2015
1Thrombotic Microangiopathies
11/2014
1Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal)
11/2014
1Stomach Neoplasms (Stomach Cancer)
10/2014
1Pathologic Neovascularization
06/2014
1Inflammation
03/2014

Drug/Important Bio-Agent (IBA)

31sorafenib (BAY 43-9006)FDA Link
08/2015 - 05/2006
27Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2015 - 06/2004
18bevacizumabFDA Link
10/2015 - 12/2007
17sunitinib (Sutent)FDA Link
10/2014 - 01/2008
15Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2015 - 01/2006
14everolimusFDA Link
11/2015 - 08/2008
13Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2015 - 08/2005
10Interleukin-2 (IL2)IBA
04/2011 - 03/2002
8axitinib (AG 013736)IBA
12/2015 - 01/2011
8temsirolimusFDA Link
10/2015 - 09/2008
8Biological Markers (Surrogate Marker)IBA
09/2015 - 03/2007
7Interferon-alpha (Interferon Alfa)FDA Link
03/2014 - 01/2006
7InterferonsIBA
07/2011 - 04/2002
6Sirolimus (Rapamycin)FDA Link
03/2014 - 08/2008
5CytokinesIBA
12/2011 - 04/2002
4Angiogenesis InhibitorsIBA
07/2015 - 12/2005
4Proteins (Proteins, Gene)IBA
01/2015 - 10/2002
4PeptidesIBA
01/2012 - 02/2004
4Interferon Alfa-2a (Interferon Alfa 2a)FDA Link
05/2010 - 12/2007
3Phosphotransferases (Kinase)IBA
12/2010 - 07/2005
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
04/2008 - 10/2002
3AntigensIBA
12/2005 - 03/2002
2Interleukin-6 (Interleukin 6)IBA
11/2015 - 06/2004
2Clear-cell metastatic renal cell carcinomaIBA
04/2015 - 08/2014
2Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
06/2014 - 03/2013
24- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA
06/2014 - 03/2013
2pazopanibIBA
05/2014 - 01/2011
2Carbonic Anhydrases (Carbonic Anhydrase)IBA
12/2012 - 10/2010
2PlatinumIBA
05/2012 - 05/2007
2Doxorubicin (Adriamycin)FDA LinkGeneric
05/2012 - 11/2009
2gemcitabineFDA Link
05/2012 - 05/2007
2Carbon MonoxideIBA
12/2011 - 11/2003
2docetaxel (Taxotere)FDA Link
07/2010 - 05/2009
2Small Interfering RNA (siRNA)IBA
01/2010 - 06/2007
2bromohydrin pyrophosphateIBA
04/2008 - 12/2005
2Messenger RNA (mRNA)IBA
06/2007 - 03/2002
2HLA-A2 Antigen (HLA A2 Antigen)IBA
02/2004 - 02/2004
1AmylasesFDA Link
12/2015
1CreatinineIBA
12/2015
1RadiumIBA
11/2015
1Monoclonal AntibodiesIBA
11/2015
1sipuleucel-T (APC8015)FDA Link
11/2015
14- acetoxy- 13- ((3- ((tert- butoxycarbonyl)amino)- 2- hydroxy- 3- phenylpropanoyl)oxy)- 1- hydroxy- 7,10- dimethoxy- 9- oxo- 5,20- epoxytax- 11- en- 2- yl benzoateFDA Link
11/2015
1abirateroneIBA
11/2015
1Androgen Receptors (Androgen Receptor)IBA
09/2015
1vasectrin IIIIBA
06/2015
1hydroxide ionIBA
06/2015
1Cystine (L-Cystine)IBA
01/2015
1Idiopathic minimal change nephrotic syndromeIBA
11/2014
1Antihypertensive Agents (Antihypertensives)IBA
11/2014
1Vascular Endothelial Growth Factor CIBA
10/2014
1RNA (Ribonucleic Acid)IBA
08/2014
1tivozanibIBA
08/2014
1Polytetrafluoroethylene (Teflon)FDA Link
08/2014
1DNA (Deoxyribonucleic Acid)IBA
07/2014
1Epidermal Growth Factor (EGF)IBA
07/2014
1Genetic Markers (Genetic Marker)IBA
07/2014
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
06/2014
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
06/2014

Therapy/Procedure

12Nephrectomy
06/2015 - 12/2005
9Drug Therapy (Chemotherapy)
11/2015 - 07/2003
5Immunotherapy
03/2009 - 03/2002
4Castration
11/2015 - 05/2009
3Radiotherapy
11/2015 - 04/2014
3Injections
10/2009 - 03/2002
2Aftercare (After-Treatment)
05/2009 - 02/2005